Drug
Romiplostim
Romiplostim: highest development phase Phase 2/3, developed by Amgen, Kyowa Kirin. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Amgen, Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| Romiplostim NCT02773290 | Phase 2/3 | Aplastic Anemia |
| Romiplostim NCT02868060 | Phase 1/2 | Immune Thrombocytopenia (ITP) |
| Romiplostim (formerly AMG 531) NCT00472290 | Not Applicable | Hematology |
Latest
No recent events.
Follow Romiplostim on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.